ed to approximately $1,196,000 in the corresponding period of 2007, an increase of approximately 23%. The Company's net loss was approximately $6,337,000 or $0.17 per basic and diluted common share for the twelve months ended December 31, 2008 compared with approximately $26,356,000 or $1.68 per basic and diluted common share for the corresponding period of 2007. Included in the Company's 2007 net loss is approximately $17,985,000 of non-cash expenses related to the conversion of approximately $18 million principal amount of the Company's notes and accrued interest thereon into shares of Nephros common stock on November 14, 2007. Such non-cash expenses included approximately $13,429,000 for the amortization of beneficial conversion features and approximately $4,556,000 for the amortization of debt discount. The 2007 net loss was reduced by approximately $330,000 in gain from exchange of debt related to the conversion of the Company's notes into shares of Nephros common stock on November 14, 2007.
Loss from operations for the twelve months ended December 31, 2008 was approximately $6,717,000 compared to approximately $7,479,000 in the corresponding period of 2007. The $762,000 reduction in operating loss resulted from an increase of $89,000 in gross profit due to increased revenue and a reduction in selling, general and administrative expenses of $673,000.
As of December 31, 2008, Nephros had cash and cash equivalents of approximately $2,306,000. The Company had approximately $7,000 invested in a certificate of deposit. The Company's independent registered public accountants, Rothstein, Kass & Company, P.C. included a going concern explanatory paragraph in its audit report covering the Company's financial statements for the year ended December 31, 2008. For information regarding the going concern qualification and management's response, please see Nephros' Annual Report on Form 10-K for the year ended December 31, 2008, whichPage: 1 2 3 4 5 6 7 Related medicine news :1
. Nephros Strengthens Commercialization Team with Addition of Marketing Executive2
. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 20083
. Nephros Reports 2008 First Quarter Financial Results4
. Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th5
. Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award6
. Nephros Receives Notice of Intention to Delist from AMEX7
. Nephros Common Stock Now Quoted in Pink Sheets8
. Nephros Provides Update on 510k Applications9
. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites10
. Haemacure Reports Third Quarter 2007 Results11
. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion